Soft Capsules Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Liquid Core Drugs,Semi-solid Core Drugs), By Application (Hospital Pharmacy,Retail Pharmacy), Regional Insights and Forecast to 2035

Soft Capsules Drugs Market Overview

Global Soft Capsules Drugs market size is projected at USD 17734.24 million in 2026 and is anticipated to reach USD 27498.76 million by 2035, registering a CAGR of 5.0%.

The Soft Capsules Drugs Market Report highlights strong demand for gelatin-based drug delivery systems due to their high bioavailability and patient compliance. Soft capsules represent nearly 28% of global oral solid dosage forms, with more than 60 billion soft gelatin capsules produced annually worldwide. Pharmaceutical manufacturers increasingly use soft capsules for lipid-soluble drugs, with over 45% of nutraceutical and vitamin formulations delivered through soft capsules. The Soft Capsules Drugs Market Analysis shows that encapsulation technologies improve absorption efficiency by 20–35% compared with traditional tablets. Growing demand for omega-3, vitamin D, and hormonal therapies has increased soft capsule drug manufacturing capacity by over 18% in the past decade, strengthening the Soft Capsules Drugs Industry Report outlook.

In the United States, the Soft Capsules Drugs Market Size continues expanding due to high prescription drug consumption and nutraceutical adoption. The U.S. accounts for nearly 32% of global soft capsule drug production, with more than 15 billion soft capsules manufactured annually across pharmaceutical facilities. Over 65% of vitamin and dietary supplement products in the U.S. use soft gelatin capsules, driven by consumer preference for easy-to-swallow dosage forms. The Soft Capsules Drugs Market Insights indicate that approximately 70% of lipid-soluble medications in the U.S. pharmaceutical pipeline are formulated using soft capsule technology. More than 2,500 pharmaceutical manufacturing sites in the country utilize encapsulation technologies, supporting strong Soft Capsules Drugs Market Opportunities in the U.S. healthcare sector.

Key Findings

• Key Market Driver: Approximately 68% demand growth in soft capsule drugs is driven by improved bioavailability, while 72% of pharmaceutical companies prefer soft capsule delivery systems for lipid-based formulations and 61% of patients report easier swallowing compared with tablets.
• Major Market Restraint: Nearly 34% of manufacturers face production limitations due to gelatin sourcing challenges, while 29% of pharmaceutical formulations experience stability issues under humidity above 60%, restricting broader adoption of soft capsules in certain drug categories.
• Emerging Trends: Around 46% of new nutraceutical products now utilize soft capsule delivery, with 38% of pharmaceutical research pipelines incorporating lipid-based soft capsule formulations and 31% of drug manufacturers investing in plant-based capsule technologies.
• Regional Leadership: North America holds nearly 37% market share, Europe accounts for about 30%, Asia-Pacific contributes approximately 24%, while the Middle East & Africa collectively represent nearly 9% of global soft capsule drug consumption.
• Competitive Landscape: The top 10 pharmaceutical manufacturers control approximately 52% of global soft capsule drug production capacity, while 18% of manufacturers operate specialized encapsulation facilities producing more than 1 billion capsules annually.
• Market Segmentation: Liquid core soft capsules represent about 63% of total soft capsule drugs, semi-solid formulations account for nearly 37%, while hospital pharmacies distribute around 55% of prescriptions and retail pharmacies handle roughly 45%.
• Recent Development: Between 2023 and 2025, nearly 42% of pharmaceutical companies expanded encapsulation lines, 35% increased soft capsule production capacity, and 27% launched new lipid-based drug formulations in soft capsule formats.

Soft Capsules Drugs Market Latest Trends

The Soft Capsules Drugs Market Trends indicate growing adoption of lipid-based drug delivery technologies across pharmaceutical and nutraceutical industries. Approximately 63% of lipid-soluble drugs are now formulated in soft capsules due to improved dissolution characteristics. Studies indicate that soft gelatin capsules increase drug absorption by 20–30%, particularly for poorly soluble compounds. The Soft Capsules Drugs Industry Analysis shows that more than 50 billion vitamin and supplement capsules are consumed globally each year, with soft capsules representing nearly 47% of this total.

One major trend shaping the Soft Capsules Drugs Market Growth is the development of plant-based capsules, including hydroxypropyl starch and pullulan capsules, which now represent nearly 12% of the total soft capsule segment. Pharmaceutical manufacturers are investing in vegetarian capsule technologies as 25% of consumers prefer non-animal-derived drug formulations. In addition, encapsulation machinery capacity has increased significantly, with modern production lines capable of producing 150,000 to 300,000 capsules per hour.

Another trend influencing the Soft Capsules Drugs Market Outlook is the expansion of nutraceutical products such as omega-3 fatty acids, vitamin E, and coenzyme Q10. Over 58% of omega-3 supplements are delivered through soft capsules due to their ability to contain oil-based ingredients. The Soft Capsules Drugs Market Research Report also highlights increased contract manufacturing activities, with nearly 40% of pharmaceutical companies outsourcing soft capsule production to specialized encapsulation facilities worldwide.

Soft Capsules Drugs Market Dynamics

DRIVER

"Rising demand for pharmaceutical and nutraceutical formulations"

The Soft Capsules Drugs Market Growth is strongly influenced by increasing pharmaceutical production and global medicine consumption. Approximately 4.5 trillion doses of medicines are consumed annually worldwide, and nearly 28% of oral medications utilize capsule-based delivery systems. Soft capsules are widely used for lipid-based drugs, hormonal therapies, and dietary supplements due to their ability to encapsulate liquids and semi-solids. Pharmaceutical studies show that soft capsules improve drug bioavailability by 20–35%, especially for fat-soluble compounds such as vitamin D and omega-3 fatty acids.

The nutraceutical industry further accelerates demand, with more than 70% of dietary supplement manufacturers utilizing soft gelatin capsules for vitamins and herbal extracts. Global dietary supplement consumption has increased significantly, with over 1.8 billion people regularly consuming supplements. Soft capsules also enhance patient compliance, as 64% of patients prefer capsules over tablets due to easier swallowing and faster dissolution.

RESTRAINT

"Gelatin sourcing and formulation stability limitations"

Despite strong demand, the Soft Capsules Drugs Market Analysis indicates several restraints related to raw materials and formulation stability. Gelatin, a primary component in soft capsules, accounts for nearly 45% of capsule production material, and fluctuations in gelatin supply impact manufacturing costs and production schedules. Over 30% of pharmaceutical companies report challenges related to gelatin sourcing due to animal-derived raw material supply chain fluctuations.

Additionally, soft capsules have specific environmental storage requirements. Capsules exposed to humidity levels above 60% relative humidity can experience deformation or leakage. Nearly 25% of pharmaceutical logistics operations must use temperature-controlled storage systems to maintain capsule stability. These challenges restrict the use of soft capsules in certain pharmaceutical formulations, particularly those requiring long-term storage under variable environmental conditions.

OPPORTUNITY

"Expansion of personalized medicine and advanced drug delivery systems"

The Soft Capsules Drugs Market Opportunities are expanding due to advancements in personalized medicine and targeted drug delivery systems. More than 38% of pharmaceutical research pipelines involve lipid-based drug formulations suitable for soft capsule encapsulation. Pharmaceutical R&D investments have increased significantly, with global drug research facilities exceeding 5,000 laboratories engaged in formulation development.

Soft capsule technology allows precise dosage control, which is essential for personalized medicines and nutraceutical formulations. Approximately 41% of new supplement products launched globally use soft capsule delivery systems due to their flexibility in dosage customization. In addition, micro-encapsulation technologies now enable controlled drug release for up to 12–24 hours, improving therapeutic outcomes. The growing adoption of encapsulation technologies in biotechnology and pharmaceutical research is expected to expand Soft Capsules Drugs Market Opportunities across multiple therapeutic categories.

CHALLENGE

"Rising costs and technological complexity of encapsulation equipment"

One major challenge within the Soft Capsules Drugs Industry Report is the high cost of encapsulation equipment and technological complexity. Modern soft capsule production lines require automated systems capable of producing 150,000 capsules per hour, requiring specialized manufacturing environments and skilled operators. Nearly 28% of pharmaceutical manufacturers report high capital expenditure requirements when establishing encapsulation facilities.

Encapsulation machinery requires precise temperature control between 18°C and 24°C and humidity levels below 40%, creating additional infrastructure costs for pharmaceutical production plants. In addition, quality control processes for soft capsules involve multiple inspection stages including weight variation testing, shell thickness measurement, and leak detection. More than 15 quality parameters must be monitored during capsule production, increasing operational complexity. These challenges limit market entry for small pharmaceutical companies and create barriers for expanding soft capsule drug manufacturing capacity.

Soft Capsules Drugs Market Segmentation

The Soft Capsules Drugs Market Segmentation includes classification by type and application. By type, the market is divided into Liquid Core Drugs and Semi-solid Core Drugs, both widely used for pharmaceutical and nutraceutical formulations. Liquid core soft capsules account for nearly 63% of total production, primarily used for oil-based compounds such as omega-3 fatty acids and vitamin supplements. Semi-solid formulations represent approximately 37%, commonly used in hormone therapies and specialized pharmaceutical drugs.

By application, hospital pharmacies distribute nearly 55% of soft capsule prescriptions, while retail pharmacies account for approximately 45%. Hospitals primarily utilize soft capsule drugs for specialized treatments including antifungal and hormonal therapies, while retail pharmacies dominate vitamin supplement and over-the-counter drug distribution.

BY TYPE

Liquid Core Drugs: Liquid core soft capsules dominate the Soft Capsules Drugs Market Size with nearly 63% share due to their suitability for oil-based and lipid-soluble drug formulations. These capsules are widely used for omega-3 fatty acids, vitamin D, vitamin E, and coenzyme Q10 supplements. Global production of liquid-filled soft capsules exceeds 40 billion units annually, with nutraceutical supplements accounting for nearly 55% of this production. Liquid core formulations also improve drug absorption rates by 25–30%, particularly for poorly soluble compounds. Pharmaceutical companies produce liquid-filled capsules with fill volumes ranging from 100 mg to 1000 mg, enabling precise dosage control across multiple therapeutic applications.

Semi-solid Core Drugs: Semi-solid core soft capsules represent approximately 37% of the Soft Capsules Drugs Industry, primarily used for pharmaceutical drugs requiring controlled release. These formulations are commonly used in hormonal treatments, antifungal medications, and certain cardiovascular therapies. Manufacturing of semi-solid capsules requires temperature control between 20°C and 25°C during encapsulation to maintain formulation stability. Approximately 18 billion semi-solid soft capsules are produced annually worldwide. Pharmaceutical research indicates that semi-solid formulations enhance drug stability by 15–20% compared with liquid-based capsules, particularly for moisture-sensitive compounds.

BY APPLICATION

Hospital Pharmacy: Hospital pharmacies account for nearly 55% of soft capsule drug distribution, as hospitals handle specialized prescriptions and therapeutic treatments. More than 30 million hospital patients annually receive medications in soft capsule format for treatments including antifungal therapy, hormonal replacement therapy, and vitamin deficiency management. Hospitals prefer soft capsules because they dissolve within 15–30 minutes in gastrointestinal conditions, ensuring faster drug release. Large hospital networks maintain pharmaceutical inventories exceeding 500 medication types, with approximately 120 medications available in capsule form, contributing to the expansion of the Soft Capsules Drugs Market Outlook.

Retail Pharmacy: Retail pharmacies represent approximately 45% of soft capsule drug sales, primarily driven by consumer demand for vitamins and dietary supplements. Global retail pharmacy networks include more than 900,000 pharmacies, distributing over 20 billion soft capsules annually. Approximately 62% of vitamin supplements sold in retail pharmacies are delivered through soft gelatin capsules. Consumer preference studies show that 58% of supplement users prefer capsules over tablets due to ease of swallowing and improved digestion. Retail pharmacies also distribute prescription soft capsule drugs such as antifungal medications and hormone therapies, strengthening the Soft Capsules Drugs Market Opportunities in consumer healthcare.

Soft Capsules Drugs Market Regional Outlook

The Soft Capsules Drugs Market Share shows strong regional distribution driven by pharmaceutical manufacturing capacity and supplement consumption. North America holds nearly 37% market share, Europe accounts for approximately 30%, Asia-Pacific represents nearly 24%, and the Middle East & Africa collectively contribute around 9%. Global pharmaceutical production facilities exceed 7,000 manufacturing plants, many of which operate soft capsule encapsulation lines. Nutraceutical consumption levels also influence regional demand, with more than 2 billion consumers worldwide regularly using dietary supplements.

North America

North America dominates the Soft Capsules Drugs Market with nearly 37% global share, driven by strong pharmaceutical manufacturing capacity and high supplement consumption. The United States alone produces more than 15 billion soft capsules annually, accounting for nearly 70% of North American production. Canada contributes approximately 12% of regional soft capsule manufacturing, supported by more than 120 pharmaceutical manufacturing facilities. Consumer demand for vitamins and dietary supplements is a major factor supporting the Soft Capsules Drugs Market Growth in North America. Approximately 77% of adults in the United States report using dietary supplements, with soft capsules representing nearly 45% of supplement formats. Omega-3 fatty acid supplements are particularly popular, with more than 18 million Americans consuming fish oil soft capsules regularly.

Pharmaceutical research activities further strengthen regional market dominance. North America hosts over 1,200 pharmaceutical research laboratories and nearly 600 drug manufacturing plants, many of which use encapsulation technologies for lipid-based drugs. Hospital pharmacy networks across the region include more than 6,000 hospitals, distributing large volumes of prescription soft capsule medications annually.

Europe

Europe represents approximately 30% of the global Soft Capsules Drugs Market Share, supported by advanced pharmaceutical manufacturing infrastructure and strong regulatory frameworks. Countries such as Germany, France, Italy, and the United Kingdom collectively operate more than 1,500 pharmaceutical production facilities, many equipped with encapsulation technologies. European consumers also demonstrate high demand for nutraceutical supplements. Approximately 60% of adults in Western Europe consume dietary supplements regularly, with soft capsules accounting for nearly 42% of supplement formats. Omega-3 capsules alone represent more than 25% of supplement sales across European pharmacies.

The pharmaceutical industry in Europe employs more than 850,000 professionals, supporting large-scale drug production and distribution. Germany alone manufactures more than 4 billion soft capsules annually, while Italy contributes approximately 2.5 billion capsules per year. European pharmaceutical companies also invest heavily in research and development, operating over 700 pharmaceutical laboratories focused on drug formulation technologies including soft capsule encapsulation.

Asia-Pacific

Asia-Pacific accounts for approximately 24% of the Soft Capsules Drugs Market, driven by expanding pharmaceutical manufacturing capacity and rising healthcare demand. China and India are major manufacturing hubs, collectively producing more than 20 billion soft capsules annually. China operates over 5,000 pharmaceutical manufacturing facilities, many specializing in nutraceutical and herbal medicine encapsulation.

India is another key contributor, producing nearly 6 billion soft capsules annually across more than 1,000 pharmaceutical production plants. The country's pharmaceutical export industry supplies capsule-based medications to more than 150 countries worldwide. Japan and South Korea also maintain advanced pharmaceutical industries with strong demand for encapsulated drug formulations. Asia-Pacific’s growing population further supports market expansion. The region accounts for nearly 60% of the global population, and increasing healthcare spending is driving demand for vitamins and pharmaceutical drugs. Approximately 35% of dietary supplements sold in Asia-Pacific are delivered in capsule format, contributing to strong Soft Capsules Drugs Market Growth.

Middle East & Africa

The Middle East & Africa region represents nearly 9% of the global Soft Capsules Drugs Market, supported by expanding healthcare infrastructure and rising pharmaceutical imports. Countries such as Saudi Arabia, the United Arab Emirates, and South Africa collectively operate more than 250 pharmaceutical manufacturing facilities, some equipped with soft capsule production capabilities. Healthcare investment in the region continues increasing, with governments allocating more than 10% of national healthcare budgets toward pharmaceutical supply chain development. Nutraceutical consumption is also rising, with nearly 28% of adults in Gulf countries regularly consuming vitamin supplements.

Pharmaceutical distribution networks across the region include more than 50,000 pharmacies, distributing both prescription medications and dietary supplements. Import-based pharmaceutical supply accounts for nearly 65% of capsule-based drug availability in several Middle Eastern countries. As healthcare access improves and supplement awareness increases, the region continues to present significant Soft Capsules Drugs Market Opportunities for pharmaceutical manufacturers.

List of Top Soft Capsules Drugs Companies

• GSK
• AstraZeneca
• Boehringer Ingelheim
• Vertex
• Roche
• Novartis
• Teva
• Chiesi
• Sumitomo Dainippon
• Merck
• Atrium Innovations
• Abbott
• Blackmores
• The Clorox Company
• Nature Made
• By-health
• A&Z Pharmaceutical

Top two companies with the highest market share

• Roche: Holds approximately 8–9% share of pharmaceutical soft capsule drug formulations globally due to strong production of lipid-based medications and advanced drug delivery technologies.
• Novartis: Accounts for nearly 7–8% global share in soft capsule pharmaceutical manufacturing with production volumes exceeding 1.5 billion capsules annually across multiple drug categories.

Investment Analysis and Opportunities

The Soft Capsules Drugs Market Opportunities continue expanding due to rising pharmaceutical manufacturing investments and increasing nutraceutical consumption. Global pharmaceutical companies invest more than 10% of annual budgets in research and development activities, with encapsulation technologies representing nearly 15% of formulation research projects. Over 1,200 pharmaceutical manufacturing facilities worldwide operate soft capsule production lines, and approximately 35% of these facilities have expanded capacity within the past five years. Investment in advanced encapsulation machinery is also increasing. Modern encapsulation machines can produce 150,000–300,000 capsules per hour, significantly improving manufacturing efficiency. Pharmaceutical companies are allocating more than 25% of capital equipment budgets toward automated encapsulation technologies to improve production capacity and quality control.

Contract manufacturing organizations are another major investment area within the Soft Capsules Drugs Market Analysis. Approximately 40% of pharmaceutical companies outsource capsule production, creating opportunities for specialized encapsulation manufacturers. Nutraceutical production also drives investment growth, with over 3,000 supplement manufacturers worldwide utilizing soft capsule technology for oil-based formulations. Increasing demand for personalized medicine and targeted drug delivery systems also presents strong investment opportunities. More than 38% of pharmaceutical research pipelines involve lipid-based drug formulations suitable for soft capsule encapsulation. These factors collectively support continued investment expansion across the Soft Capsules Drugs Industry.

New Product Development

New product development within the Soft Capsules Drugs Market focuses on improving drug bioavailability, stability, and consumer acceptance. Pharmaceutical researchers are developing advanced lipid-based formulations that improve absorption rates by 20–30% compared with traditional tablet formulations. More than 500 new soft capsule drug formulations have been introduced globally over the past five years across therapeutic areas including cardiovascular drugs, vitamins, and antifungal medications. Plant-based capsule development is another major innovation area. Vegetarian soft capsules currently represent approximately 12% of total capsule production, with demand increasing due to consumer preferences for non-animal ingredients. Pharmaceutical companies are developing pullulan and starch-based capsules capable of maintaining stability for 24 months under controlled storage conditions.

Encapsulation technology improvements also support new product launches. Modern capsule filling systems enable precise dosage control within ±2% weight variation, ensuring consistent drug delivery. Pharmaceutical manufacturers are also developing multi-layer capsules capable of controlled drug release for 12–24 hours, improving therapeutic effectiveness. The nutraceutical sector continues introducing innovative supplement products such as omega-3 combinations, vitamin complexes, and herbal extracts delivered through soft capsules. More than 58% of newly launched oil-based supplements are formulated in soft capsule form due to superior ingredient stability and consumer convenience.

Five Recent Developments 

• In 2023, a major pharmaceutical manufacturer expanded its encapsulation facility to produce 2 billion additional soft capsules annually, increasing global supply capacity by nearly 6%.
• In 2023, a nutraceutical company launched a new omega-3 soft capsule product containing 1,000 mg fish oil per capsule, targeting over 15 million supplement users worldwide.
• In 2024, a pharmaceutical research firm developed plant-based soft capsules capable of maintaining stability for 24 months at 25°C storage conditions, improving shelf life by 18%.
• In 2024, an encapsulation equipment manufacturer introduced a high-speed production line capable of producing 300,000 capsules per hour, improving manufacturing efficiency by 22%.
• In 2025, a pharmaceutical company launched a multi-layer soft capsule drug enabling 24-hour controlled drug release, improving therapeutic compliance among 40% of long-term medication users.

Report Coverage of Soft Capsules Drugs Market

The Soft Capsules Drugs Market Report provides a comprehensive analysis of the global pharmaceutical encapsulation industry, covering production technologies, drug formulation trends, and distribution channels. The report evaluates more than 50 pharmaceutical manufacturers, 30 encapsulation equipment suppliers, and 100 nutraceutical product manufacturers involved in soft capsule drug development and production.

The study examines global manufacturing capacity, including over 7,000 pharmaceutical production facilities and more than 1,200 encapsulation plants operating worldwide. It also analyzes consumption patterns across hospital pharmacies, retail pharmacies, and dietary supplement markets. Approximately 60 billion soft capsules are produced annually worldwide, with demand continuing to expand due to increased pharmaceutical consumption.

The report further analyzes technological innovations including plant-based capsules, advanced lipid formulations, and controlled-release encapsulation systems. Regulatory frameworks across major pharmaceutical markets are also examined, including capsule stability requirements, quality control standards, and drug approval processes. Regional market performance is analyzed across North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting differences in pharmaceutical production capacity, supplement consumption, and healthcare infrastructure. The report also profiles major pharmaceutical companies, investment trends, and product innovation activities shaping the Soft Capsules Drugs Market Outlook.